Alcohol Use Disorder Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies

 Breaking News
  • No posts were found

Alcohol Use Disorder Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies

Alcohol Use Disorder Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 30+ key pharma and biotech companies are working on 30+ pipeline drugs in the Alcohol Use Disorder therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Alcohol Use Disorder Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Alcohol Use Disorder Market. 

The Alcohol Use Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Alcohol Use Disorder Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Alcohol Use Disorder and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Alcohol Use Disorder market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, featured press releases from company/university websites, industry-specific third-party sources, etc.  

Alcohol Use Disorder Pipeline Analysis

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Alcohol Use Disorder Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion

  • Intradermal

  • Intramuscular

  • Intranasal

  • Intravenous

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

Molecule Type

Alcohol Use Disorder Products have been categorized under various Molecule types such as

  • Gene therapies

  • Small molecule

  • Vaccines

  • Polymers

  • Peptides

  • Monoclonal antibodies

Learn How the Ongoing Clinical & Commercial Activities will Affect the Alcohol Use Disorder Therapeutic Segment @

Alcohol Use Disorder Therapeutics Landscape

There are approx. 30+ key companies developing Alcohol Use Disorder therapies. Currently, Adial Pharmaceuticals is leading the therapeutics market with its Alcohol Use Disorder drug candidates in the most advanced stage of clinical development.

The Leading Players in the Alcohol Use Disorder Therapeutics Market Include:

  • ADial Pharmaceuticals

  • R-Pharm|Synergy Research

  • Arbor Pharmaceuticals

  • Laboratorio Farmaceutico

  • Gilead Sciences

  • Kinnov Therapeutics

  • Opiant Pharmaceuticals

  • MediciNova

  • Bioprojet

  • Corcept Therapeutics

  • Pfizer

  • Dicerna Pharmaceuticals, Inc.

  • Organon

  • Confluence Pharmaceuticals

  • Adial Pharmaceuticals

  • MediciNova

  • Corcept Therapeutics

  • Astellas Pharma

  • Bioprojet

  • Alkermes

  • Lundbeck

  • Otsuka Pharmaceuticals

And Many Others

Alcohol Use Disorder Emerging and Marketed Drugs Covered in the Report Include

  • Ondansetron: Adial Pharmaceuticals

  • MN-166: MediciNova

  • ANS-6637: Amygdala Neurosciences

  • GET73: Laboratorio Farmaceutico

  • PT150: Pop Test Oncology

  • WIL-1903: Whanin Pharmaceutical

  • CYB003: Cybin

  • BXCL501: BioXcel Therapeutics

  • PT150 : Pop Test Oncology

  • DCR-AUD: Dicerna Pharmaceuticals

  • MAP4343: Mapreg

  • KT 110: Kinnov Therapeutics

  • Ibudilast/MN-166: MediciNova

  • AD04/Ondansetron: Adial Pharmaceuticals

  • MN-166 (ibudilast): MediciNova

  • AD04 (ondansetron): Adial Pharmaceuticals

  • CORT118335 (mifepristone): Corcept Therapeutic

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Alcohol Use Disorder Current Treatment Patterns

4. Alcohol Use Disorder – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Alcohol Use Disorder Late Stage Products (Phase-III)

7. Alcohol Use Disorder Mid-Stage Products (Phase-II)

8. Alcohol Use Disorder Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Alcohol Use Disorder Discontinued Products

13. Alcohol Use Disorder Product Profiles

14. Key Companies in the Alcohol Use Disorder Market

15. Key Products in the Alcohol Use Disorder Therapeutics Segment

16. Dormant and Discontinued Products

17. Alcohol Use Disorder Unmet Needs

18. Alcohol Use Disorder Future Perspectives

19. Alcohol Use Disorder Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Osteochondrodysplasia Market

“Osteochondrodysplasia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Osteochondrodysplasia market trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). Moreover, it covers the current treatment practices, emerging drugs, market share of individual therapies, treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Osteochondrodysplasia market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States